Preparation and characterization of amoxapine- and naringin-loaded solid lipid nanoparticles: drug-release and molecular-docking studies - supplementary dataset

Aim: Amoxapine (AMX) has been reported to be metabolized by CYP3A4 and CYP2D6. Naringin (NG) has
been reported to inhibit CYP enzymes. Therefore, the current work was designed to develop AMX solid
lipid nanoparticles (AMX-SLNs) and NG-SLNs for better therapeutic performance. Materials & methods:
AMX-SLNs and NG-SLNs were prepared and characterized. AMX and NG interactions with CYP450s were studied with molecular docking to rationalize the effectiveness of the combination. Results: AMX-SLNs
and NG-SLNs showed nanometric size with a sustained in vitro drug-release profile. NG showed a higher
predicted binding affinity for CYP3A4 and CYP2D6, suggesting the potential for inhibition. Conclusion:
The developed formulations were thoroughly characterized along with molecular docking data indicating
promising AMX and NG combinations that may show good therapeutic activity.